Avidity Biosciences (RNA) Earnings Date, Estimates & Call Transcripts $29.77 +3.03 (+11.33%) Closing price 04/2/2025 04:00 PM EasternExtended Trading$28.64 -1.14 (-3.81%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Earnings Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock Avidity Biosciences Latest Earnings SummaryUpcoming Q1 Earnings DateMay. 8Before Market OpensEstimatedActual EPS (Feb. 27) -$0.80 Missed By -$0.04 Consensus EPS (Feb. 27) -$0.76 Avidity Biosciences announced Q4 2024 earnings on February 27, 2025, reporting an EPS of -$0.80, which missed analysts' consensus estimates of -$0.76 by $0.04. Quarterly revenue was reported to be $2.97 million, above analysts' expectations of $1.74 million. With a trailing EPS of -$2.89, Avidity Biosciences' earnings are expected to decrease next year, from ($2.89) to ($3.34) per share. RNA Upcoming EarningsAvidity Biosciences' next earnings date is estimated for Thursday, May 8, 2025, based off prior year's reporting schedules. Get Avidity Biosciences Earnings Alerts Want to stay updated on the latest earnings announcements and upcoming reports? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Avidity Biosciences and other key companies, straight to your inbox. Enter your email to sign up for newsletter Sign Up Skip Charts & View Estimated and Actual Earnings DataRNA Earnings Estimates and Actuals by QuarterEarnings Estimates and Acutals by Quarter Chart DescriptionThe chart below shows up to four years of a company's earnings history. The dark blue line represents the company's actual earnings per share. The light blue area represents the range of Wall Street analysts' earnings estimates for each quarter.RNA Estimated and Actual Revenue by QuarterEstimated Revenue and Actual Revenue by Quarter Chart DescriptionThe chart below shows up to four years of a company's revenue history. The dark blue line represents the company's actual revenue. The light blue line represents the company's estimated revenue based on the consensus of Wall Street analysts for each quarter. Remove Ads Avidity Biosciences Analyst EPS EstimatesQuarterNumber of EstimatesLow EstimateHigh EstimateAverage EstimateQ1 20251-$0.88-$0.88-$0.88Q2 20251-$0.93-$0.93-$0.93Q3 20251-$0.99-$0.99-$0.99Q4 20251-$1.05-$1.05-$1.05FY 20254($3.85)($3.85)($3.85) Remove Ads Avidity Biosciences Earnings History by Quarter Custom Range 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years 5 Years 10 Years Time Frame * Start Date * End Date Export to Excel DateQuarterConsensus EstimateReported EPSBeat/MissGAAP EPSRevenue EstimateActual RevenueDetails 5/8/2025(Estimated)-------2/27/2025Q4 2024-$0.76-$0.80 -$0.04-$0.80$1.74M$2.97M11/7/2024--$0.79-$0.65+$0.14-$0.65$7.09M$2.34M8/9/2024--$0.76-$0.65+$0.11-$0.65$7.09M$2.05M5/15/2024--$0.81-$0.79+$0.02-$0.79$7.09M$3.54M2/28/2024Q4 2023-$0.54-$0.79 -$0.25-$0.79$32.08M$2.19M11/8/2023Q3 2023-$0.76-$0.71+$0.05-$0.71$2.09M$2.82M8/8/2023Q2 2023-$0.84-$0.66+$0.18-$0.66$2.09M$2.32M5/9/2023Q1 2023-$0.90-$0.74+$0.16-$0.74$2.08M$2.23M Avidity Biosciences Earnings - Frequently Asked Questions When is Avidity Biosciences's earnings date? Avidity Biosciences has not confirmed its next earnings publication date, but the company's estimated earnings date is Thursday, May 8th, 2025 based off last year's report dates. Learn more on RNA's earnings history. Did Avidity Biosciences beat their earnings estimates last quarter? In the previous quarter, Avidity Biosciences (NASDAQ:RNA) missed the analysts' consensus estimate of ($0.76) by $0.04 with a reported earnings per share (EPS) of ($0.80). Learn more on analysts' earnings estimate vs. RNA's actual earnings. How much revenue does Avidity Biosciences generate each year? Avidity Biosciences (NASDAQ:RNA) has a recorded annual revenue of $10.90 million. How much profit does Avidity Biosciences generate each year? Avidity Biosciences (NASDAQ:RNA) has a recorded net income of -$212.22 million. RNA has generated -$2.89 earnings per share over the last four quarters. What is Avidity Biosciences's EPS forecast for next year? Avidity Biosciences's earnings are expected to decrease from ($2.89) per share to ($3.34) per share in the next year. More Earnings Resources from MarketBeat Related Companies Intra-Cellular Therapies Earnings Results Genmab A/S Earnings Results Dr. Reddy's Laboratories Earnings Results Moderna Earnings Results Viatris Earnings Results Ascendis Pharma A/S Earnings Results Qiagen Earnings Results Roivant Sciences Earnings Results Lantheus Earnings Results BridgeBio Pharma Earnings Results Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Intuitive Machines Gains After Earnings Beat, NASA Missions AheadCintas Delivers Earnings Beat, Signals More Growth AheadNike Stock Dips on Earnings: Analysts Weigh in on What’s NextAfter Massive Post Earnings Fall, Does Hope Remain for MongoDB?Semtech Rallies on Earnings Beat—Is There More Upside?These 3 Q1 Earnings Winners Will Go HigherWhat Is the Price-to-Earnings (P/E) Ratio? Remove Ads This page (NASDAQ:RNA) was last updated on 4/3/2025 by MarketBeat.com Staff From Our PartnersBITCOINDid you miss out on the 1000%+ gains of Bitcoin over the past 5 years? If so, you don't want to miss this.....Awesomely, LLC | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
